StockTwits, founded in 2008 by Howard Lindzon and Soren Macbeth, is a leading social media platform designed specifically for investors and traders to share real-time market insights, ideas, and strategies. Headquartered in New York City, the company pioneered the use of "cashtags" (e.g., $AAPL) to organize financial discussions, initially integrating with Twitter before evolving into a standalone network.
AstraZeneca said on Friday that the full results from the two trials will be shared with regulatory authorities and presented at an upcoming medical meeting.
According to a Reuters report, Chevron CFO Eimear Bonner said share repurchases in 2025 could be between $11.5 billion and $13 billion, which would be at the lower end of the company's guidance of $10 billion to $20 billion.
Classover’s move to adopt Solana in its treasury follows a growing trend among micro-cap companies such as Upexi and Janover, which are also shifting to Solana-focused reserve strategies.
Apple and Amazon stocks traded in the red pre-market despite upbeat earnings after citing concerns about the impact of Trump’s tariffs on their financial results.
The company expects to generate free cash flow between $1.10 billion and $1.20 billion this year, compared with its earlier forecast of between $1.03 billion and $1.13 billion.
While analysts remain optimistic on Adani Ports, they highlight key resistance levels and recommend a wait-and-watch strategy for new investors until a decisive breakout.
While analysts remain optimistic on Adani Ports, they highlight key resistance levels and recommend a wait-and-watch strategy for new investors until a decisive breakout.
The company said it remains confident in its strategy and continues to see a path to achieving positive operating income in 2026, despite the uncertainties.
The stock has seen a surge in trading volumes and strong institutional interest following a major $73 million deal, with technical indicators supporting the bullish view.
Equitymaster sees long-term upside in five undervalued stocks with strong earnings, sectoral tailwinds, and expansion plans across auto, staffing, drilling, pharma-tech, and chemicals.
Phathom's VOQUEZNA prescriptions rose 8% sequentially in Q1, with over 390,000 cumulative fills and expanding adoption across both GI and primary care.
Brokerages and SEBI-registered analysts maintained bullish long-term views on Eternal. Improved revenue, strategic exits from unprofitable verticals, and technical strength also boosted sentiment.
The surge in Adani Enterprises’ Q4 profit was largely attributed to a one-off gain from the partial stake sale in its Wilmar joint venture, while revenue fell 7% year-on-year.
The spotlight will likely be on the April non-farm payrolls report. Economists, on average, expect 133,000 job gains for the month, notably slower than the 228,00 pace for March.
Harley-Davidson’s better-than-expected Q1 results and ongoing cost-cutting efforts offered some reassurance to investors despite concerns over weakening U.S. retail sales and long-term demand trends.
The shale oil producer lowered its full-year capital expenditure plan to a range of $5.8 billion to $6.2 billion, a $200 million reduction at the midpoint.
China’s spokesperson said if the U.S. wants to talk, it has to show sincerity and be prepared to correct its wrong practices and cancel the unilateral tariffs.
Organon shares sank 27% Thursday after slashing its dividend by over 90%, triggering analyst downgrades and investor concern. Some retail traders, however, remained upbeat, citing the company’s focus on debt reduction and long-term growth.
TransCode Therapeutics shares surged nearly 39% after reporting promising Phase 1a trial results for its metastatic cancer drug TTX-MC138, with strong retail interest and no major safety concerns.
Adial Pharmaceuticals jumped to its highest level since February after receiving a U.S. patent for its precision medicine approach to treating addiction. The patent supports the use of AD04 in patients with specific genetic markers.
The company has adjusted its full-year revenue guidance to $4.1 billion to $4.21 billion, reflecting the benefits of foreign exchange impacts, up from its previous estimate of $4.06 billion to $4.17 billion.
Summers also countered Treasury Secretary Scott Bessent’s view that bond yield at the shorter end of the curve indicates the Fed should cut interest rates.
The company logged sales of 372,615 new-energy passenger vehicles and 7,474 commercial vehicles during the month, including the 79,086 vehicles sold outside China.
The company reported first-quarter revenue of $108 million, down from $167 million in the corresponding period of 2024, and below an analyst estimate of $115.32 million, as per FinChat data.
The company now expects net income attributable to shareholders for the full year to be $8.2 billion to $10.1 billion, down from its previous estimate of $11.2 billion to $12.5 billion.
H.C. Wainwright initiated coverage at ‘Buy’ and a $480 price target earlier this week, citing its aggressive Bitcoin accumulation strategy as grounds for a premium valuation.
Gold prices extended their slide on Thursday, trading at around $3,220 per ounce during pre-market hours, as traders welcomed signs of progress in trade talks between the U.S. and countries facing President Trump's hefty tariff hikes.
The railroad operator cut its adjusted earnings per share growth expectations for 2025 to between 10% and 14% from between 12% and 18%, projected earlier.
The company reported a net income of $879 million, or $1.28 per share, for the reported quarter, compared to $800 million, or $1.10 per share, a year earlier.
CFO Amy Hood said on the call that fourth-quarter capital expenditure will rise sequentially from the $21.4 billion spent in the previous three-month period.
The investor argues the U.S. is emerging from a three-year “stealth recession” and forecasts a productivity-driven economic boom led by innovation-focused companies. She expects falling interest rates, lower inflation
Q32 Bio shares drew renewed attention on Wednesday after the FDA granted Fast Track designation to its experimental alopecia areata treatment, bempikibart. The designation could accelerate development and review of the Phase 2-stage therapy.
CFO Akash Palkhiwala acknowledged the uncertainty around the impact of the global trade landscape on demand across the company’s businesses, according to Koyfin’s transcript.
